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Dual blockade of the renin-angiotensin system versus maximal tensin-converting enzyme (ACE) inhibition, has been
recommended dose of ACE inhibition in diabetic nephropathy. shown to reduce albuminuria, to diminish loss of kidney
Background. Albuminuria and hypertension are predictors function, and to improve survival in type 1 patients withof poor renal and cardiovascular outcome in diabetic patients.
diabetic nephropathy (DN) [1–4]. Studies of diabetic andWe tested whether dual blockade of the renin-angiotensin system
nondiabetic kidney disease suggest the initial degree of(RAS) with both an angiotensin-converting enzyme (ACE) in-
hibitor and an angiotensin II receptor blocker (ARB) is supe- reduction in albuminuria after blockade of the renin-
rior to maximal recommended dose of ACE inhibitor in type 1 angiotensin system (RAS) system predicts an attenuated
diabetic patients with diabetic nephropathy (DN). rate of decline in glomerular filtration rate (GFR), asMethods. We performed a randomized, double-blind, cross-
reviewed by Rossing [1]. As a consequence, albuminuriaover trial with 8 weeks treatment with placebo and irbesartan
may serve as a surrogate endpoint for monitoring treat-300 mg (once daily), added on top of enalapril 40 mg (once
daily). We included 24 type 1 patients with DN. At the end of ment efficacy and prognosis in DN [5].
each treatment period, albuminuria, 24-hour blood pressure, Dual blockade of the RAS with both ACE inibition
and glomerular filtration rate (GFR) were measured. and angiotensin II receptor blocker (ARB) has beenResults. Values on ACE inhibitors  placebo were: albu-
suggested as superior to monotherapy in diabetic pa-minuria [mean (95% CI)], 519 (342 to 789) mg/24 hours; blood
tients with microalbuminuria [6] and in DN [7, 8] andpressure [mean (SEM)], 131 (3)/74 (1) mm Hg, and GFR [mean
(SEM)], 65 (5) mL/min/1.73 m2. Dual blockade of the RAS nondiabetic nephropathy [9]. However, until now, all
induced a reduction in albuminuria [mean (95% CI)] of 25% studies have compared dual blockade of the RAS with
(15, 34) (P  0.001), a reduction in systolic blood pressure of
submaximal doses of monotherapy and, as a conse-8 mm Hg (4, 12) (P  0.002), and a reduction of 4 mm Hg
quence, beneficial effects may have been overestimated.(2, 7) (P 0.003) in diastolic blood pressure. GFR and plasma
potassium remained unchanged during both treatment regimes. Therefore, we tested if the addition of the maximal
Dual blockade was safe and well tolerated. recommended dose ARB offers more complete block-
Conclusion. Dual blockade of the RAS is superior to maxi- ade of the RAS in type 1 diabetic patients with DN
mal recommended dose of ACE inhibitors with regard to low-
receiving maximal recommended dose of ACE inhibitors.ering of albuminuria and blood pressure in type 1 patients with
DN. Long-term trials are needed to further establish the role
of dual blockade of the RAS in renal and cardiovascular pro-
METHODStection.
Subjects
From Steno Diabetes Center, we included 24 type 1
Albuminuria and hypertension are predictors of poor diabetic patients with DN. DN was diagnosed clinically
renal and cardiovascular outcome in patients with diabe- if the following criteria were fulfilled: persistent albumin-
tes [1, 2]. Antihypertensive treatment, especially angio- uria 300 mg/24 hours in two out of three consecutive
determinations, presence of diabetic retinopathy, and no
other kidney or renal tract disease [10, 11]. All patients
Key words: ACE inhibition, albuminuria, angiotensin II receptor block- had been dependent on insulin treatment from the timeade, blood pressure, cholesterol, diabetic nephropathy, dual blockade
of diagnosis and received at least two daily injections ofof the RAS, glomerular filtration rate, renin-angiotensin system, type I
diabetes. insulin. Patients were on a diabetic diet (45% to 55%
carbohydrates, 30% to 35% fat, and 15% to 20% pro-Received for publication October 24, 2002
tein) without restriction in sodium or protein intake.and in revised form December 12, 2002
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ceptives, age 18 years, alcohol or medicine abuse, in- 30 minutes during nighttime (from 11.00 p.m. to 7.00 a.m.).
Values were averaged for each hour before calculatingability to understand the patient information, contraindi-
cation to treatment with ACE inhibitors or ARBs, systolic the mean 24-hour day and night arterial blood pressures.
GFR was measured after a single intravenous injectionblood pressure 100 mm Hg, GFR 30 mL/min, heart
failure, myocardial infarction, or coronary by-pass within of 3.7 MBq 51Cr-ethylenediaminetetraacetic acid (EDTA)
at 8.30 a.m. by following the plasma clearance of thethe last 6 months. Twenty-four patients were included
in the study. tracer for 4 hours [12, 13]. Extra renal loss was corrected
for by subtracting 3.7 mL/min [14]. The small underesti-
Design mation (10%) of 51Cr-EDTA renal clearance versus renal
clearance of inulin was corrected for by multiplying theWe performed a randomized, double-blind, placebo-
controlled, crossover trial. Each patient received 8 weeks EDTA clearance by 1.10 [14]. The results were standard-
ized for 1.73 m2 body surface area. The mean day-to-daytreatment with irbesartan 300 mg once daily and 8 weeks
of placebo in random order. The study medication was coefficient of variation in GFR is 4% in our laboratory.
From venous samples, hemoglobin, plasma potassium,added on top of the patient’s usual antihypertensive
treatment, including enalapril 40 mg once daily. This sodium, creatinine, and fasting cholesterol concentra-
tions were determined. Plasma potassium was measuredwas left unchanged throughout the study except in two
patients, who had the dose of diuretics increased (see by an indirect ion-selective method, normal range 3.2 to
4.7 mmol/L (BM/HITACHI system, Boehringer Mann-Results section). All patients had received 40 mg of ena-
lapril for more than 3 months prior to the study. The heim GmbH, Roche Lab Systems, Mannheim, Germany).
Our hemoglobin method has a normal range in femalesrandomization was done by the manufacturing com-
pany’s local office (Sanofi-Synthelabo, Copenhagen, Den- of 7 to 10 mmol/L and 8 to 11 in males (Sysmex SF
3000, Sysmex Corp., Kobe, Japan). Hemoglobin A1c wasmark). The code was kept in a concealed envelope and
not broken until all data were entered in a database after measured by high-performance liquid chromatography
(HPLC) (normal range 4.1% to 6.1%) (Variant, Bioradthe last patient visit. Patients visited the clinic 2 and 8
weeks after start of each treatment period. Blood pres- Laboratories, Hercules, CA, USA). Blood samples for
renin concentration were taken after 30 minutes supinesure, plasma potassium, and plasma creatinine were mea-
sured 2 weeks after the beginning of each treatment rest and plasma concentration was determined using the
principle of antibody trapping [15] as modified by Millarperiod for safety reasons. At the end of each treatment
period, we assessed clinical end points, including the et al [16].
primary end point of albuminuria and the secondary end
Statisticspoints of 24-hour arterial blood pressure and GFR.
Drug compliance was assessed by tablet counts. The Before carrying out the study, we calculated the stan-
dard deviation (SD) (log scale, 0.1771) of the mean dif-study protocol was in accordance with the Declaration
of Helsinki and was approved by the local ethical com- ference in urinary albumin excretion rate in three con-
secutive 24-hour urine samples collected twice withinmittee. All patients gave their informed consent to par-
ticipate in the study. 3 months in 36 type 1 patients with DN. On the basis of
these data, a sample-size calculation revealed a necessary
Methods minimum of 16 patients to detect a 25% difference in
change in urinary albumin excretion rate (  0.05 andAlbuminuria was determined by three consecutive
24-hour urine collections, completed immediately before   0.80).
Normally distributed variables are expressed as meaneach visit at the end of each treatment period (Turbidim-
etry, Cobas Mira Plus, Roche, Montclair, NJ, USA). To (SEM). Values for albuminuria and renin were logarith-
mically transformed and expressed as geometric meancorrect the reduction in 24-hour albuminuria for changes
in GFR and plasma albumin, we constructed the follow- (95% CI) because of their positively skewed distribution.
Changes in these variables between different treatmentsing “fractional clearance” index: [24-hour albuminuria]/
([plasma albumin concentration]  [GFR]). In addition, are expressed in percent.
Test for time and carryover effects was performed assodium, urea, creatinine, and carbamid excretion in the
urine were determined (Cobas Mira Plus, Roche, Mont- described by Altman et al [17]. Data were analyzed using
linear mixed models [18]. The software used was R (http://clair, NJ, USA).
Arterial blood pressure after each treatment period www.r-project.org) and SPSS 11.0 (SPSS, Inc., Chicago,
IL, USA). The adapted model was one with fixed effectswas assessed by 24-hour ambulatory blood pressure mea-
surements with the Takeda TM2420 device; models 6 and of treatments and visit and a random effect for person
included to account for the person-dependencies in data.7 (A&D, Medical, Inc., Tokyo, Japan). A measurement
of the blood pressure was performed every 15 minutes For the simplest models the P value and effects corre-
spond to results obtained from paired t test and two-during daytime (from 7.00 a.m. to 11.00 p.m.) and every
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Table 1. Baseline clinical data in 24 type 1 patients with diabetic to the addition of irbesartan was not related to placebo
nephropathy (DN)
level of blood pressure.
Age years 42 (9) Linear regression analysis showed a correlation be-
Gender male/female 17/7 tween the change in diastolic blood pressure and theDuration of diabetes years 31 (9)
change in albuminuria when comparing dual blockadeDuration of DN years 13 (5)
Retinopathy background/proliferative 5/19 with placebo (R  0.63, P  0.001, Fig. 1). A similar
Total number of antihypertensive drugs (1/2/3/4) 5/12/6/1 correlation between change in albuminuria and changeNo. of patients receiving diuretics thiazide/furosemidea 8/11
in mean arterial blood pressure was seen (R  0.54, P No. of patients receiving calcium channel blockersb 6
No. of patients receiving statins 10 0.009). No correlation between change in systolic blood
Values presented are mean (SD). pressure and the change in albuminuria was seen (R 
a Dose, median (range): 120 (20 to 500) mg daily; b in addition to angiotensin- 0.30, P  0.17). We also found a correlation betweenconverting enzyme (ACE) inhibitors and diuretics
the change in plasma renin concentration and the change
in albuminuria (R  0.52, P  0.011, Fig. 2) and change
in diastolic blood pressure (R  0.64, P  0.001, Fig. 3).
Multivariate analysis revealed that decline in diastolicway analysis of variance, but these models allow for more
blood pressure were associated with decline in albumin-elaborate exploration of the material. Tests for presence
uria (P  0.001), whereas treatment type and visit wereof effects were performed as likelihood ratio tests, and
not (R 2 (adjusted)  0.36, P  0.001).final estimates were reported as restricted maximum likeli-
We observed no changes in GFR or plasma creatininehood (REML) estimates [18]. Linear regression analyses
during treatment with dual blockade of the RAS com-were made between the changes in arterial blood pressure,
pared to placebo (Table 2). Changes in other laboratorychanges in albuminuria, and changes in renin concentra-
parameters are shown in Table 2. Dual blockade of thetion. A multiple regression model with albuminuria as
RAS induced a significant decline in hemoglobin and ana dependent variable and blood pressure, treatments,
increase in hemoglobin A1c. Triglyceride and plasma veryand visit as independent variables were performed. A P
low-density lipoprotein (VLDL) were unchanged through-value 0.05 was considered significant (two-tailed).
out the study. Urinary sodium excretions were 152 and
148 mmol/24 hours during placebo and irbesartan treat-
ment, respectively (NS). No correlation between changesRESULTS
in albuminuria and changes in plasma cholesterol orTwenty four patients were randomized in the trial of
plasma low-density lipoprotein (LDL) were demonstrated.which all completed the study. Baseline characteristics
No carryover effect was seen. Statistical evidence of a
are shown in Table 1. The median (range) duration of minor decline in albuminuria and 24-hour blood pressure
both treatment periods was 58 days (45 to 76 days) and through the study period was demonstrated (time effect).
compliance as assessed by tablet count was median (range) Our statistical model for evaluation of treatment effects
100% (71% to 100%) (no difference between irbesartan included and corrected for the observed time effect. Esti-
and placebo). mates of all treatment effects were the same with and
Albuminuria and 24-hour blood pressure were signifi- without correction for time effect; however, all calcula-
cantly reduced by the addition of irbesartan 300 mg com- tions were performed with the model including visit (time
pared to placebo (Table 2). effect).
Dual blockade of the RAS induced an additional re-
Adverse effectsduction in albuminuria (mean, 95% CI) of 25% (15,
Six patients experienced signs of transient hypotension34) compared to placebo. When looking at “fractional
(N 4) or described general tiredness (N 2) after startclearance” index, dual blockade induced an additional
of dual blockade treatment. Plasma potassium increasedreduction in albuminuria of (mean, 95% CI) 22% (11, 31)
to5.2 mmol/L in two patients (one after start of placebocompared to placebo. The decline in albuminuria was
treatment and one after the start of irbesartan treat-independent of the placebo level of albumin excretion.
ment). Both patients had GFR 40 mL/min/year andAn additional reduction in 24-hour systolic blood pres-
were treated with an increase of 50% in furosemide dose.sure on dual blockade of 8 mm Hg (4, 12) (P  0.002)
Hemoglobin decreased (Table 2); however, none of theand a reduction of 4 mm Hg (2, 7) (P  0.003) diastolic
patients needed treatment for anemia during the study.compared to placebo was demonstrated. The decline of
No other adverse effects were reported.
mean arterial blood pressure when adding irbesartan
was 5 mm Hg (3, 8) (P  0.001). No significant changes
DISCUSSIONwere found in the 24-hour mean heart rate. The reduc-
tion in blood pressure was sustained both during daytime Our study is the first to demonstrate an effect of dual
blockade of the RAS on albuminuria and 24-hour bloodand nighttime (Table 2). The antihypertensive response
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Table 2. Dual blockade of the renin-angiotensin system (RAS) with irbesartan 300 mg once daily in 24 type 1 patients with diabetic
nephropathy (DN) treated with enalapril 40 mg once daily
Enalapril 40 mg  Enalapril 40 mg 
placebo irbesartan 300 mg Mean difference (95% CI) P value
Albuminuria mg/24 hour a 519 (342,789) 373 (224,622) 25% (34, 15) 0.001
24-hour blood pressure mm Hg 131 (3)/74 (1) 123 (3)/70 (2) 8 (12, 4)/4 (7, 2) 0.002/0.003
Day (7-23) 135 (3)/76 (1) 128 (4)/73 (2) 7 (12, 2)/4 (6, 1) 0.012/0.018
Night (23-7) 118 (3)/70 (2) 110 (3)/63 (2) 9 (14, 3)/6 (9, 3) 0.007/0.001
Glomerular filtration rate mL/min/1.73 m 2 65 (5) 63 (5) 3 (1, 7) 0.222
Plasma renin concentration mU/La 177 (86, 364) 283 (133, 602) 64% (8, 150) 0.031
Plasma creatinine lmol/L 134 (7) 139 (7) 4 (4, 13) 0.290
Plasma potassium mmol/L 4.2 (0.1) 4.3 (0.1) 0.1 (0.1, 0.3) 0.178
Hemoglobin mmol/L 8.0 (0.2) 7.6 (0.2) 0.4 (0.6, 0.1) 0.005
Hemoglobin A1C % 9.1 (0.3) 9.3 (0.2) 0.3 (0.1, 0.5) 0.019
Plasma cholesterol mmol/L 5.0 (0.2) 4.7 (0.2) 0.3 (0.6, 0.0) 0.109
Plasma low-density lipoprotein mmol/L 2.6 (0.2) 2.4 (0.2) 0.3 (0.6, 0.0) 0.052
Plasma high-density lipoprotein mmol/L 1.7 (0.1) 1.7 (0.1) 0.0 (0.1, 0.1) 0.876
Values represented are mean (SEM).
aMean (95% CI).
Fig. 1. Linear regression analysis between the change in diastolic blood
Fig. 2. Linear regression analysis between the change in plasma reninpressure and the change in albuminuria (LN) in type 1 patients with
concentration (LN) and the change in albuminuria (LN) in type 1diabetic nephropathy (DN) treated with dual blockade of the renin-
patients with diabetic nephropathy (DN) treated with dual blockadeangiotensin system (RAS).
of the renin-angiotensin system (RAS).
pressure beyond what is obtainable with maximal recom- tion, ACE inhibitors decreased the degradation of brady-
mended doses of ACE inhibitors alone in diabetic pa- kinin, a powerful vasodilator [19]. However, an insuffi-
tients with DN. Dual blockade of the RAS with high cient response to ACE inhibitor might be explained by
doses of ACE inhibitors and ARB was safe and well incomplete blockade of the ACE enzyme or by the gen-
tolerated. eration of angiotensin II by ACE-independent pathways
Six patients (25%) experienced transient symptoms such as chymase [20]. The incomplete blockade possibly
of hypotension or tiredness. In all patients except one, explains the observation that plasma angiotensin II levels
symptoms disappeared within the 8 weeks’ treatment return to normal after chronic ACE inhibitor treatment,
period. These side effects were related to the degree of a phenomenon called “ACE escape” [21]. Treatment
drop in diastolic blood pressure, but not to placebo blood with ARB may result in more complete blockade of the
pressure level or the number of antihypertensive agents unfavorable actions of angiotensin II mediated through
taken. the angiotensin II type 1 receptor. However, new data
The rationale for dual blockade of the RAS is based from animal studies indicate that some of the deleterious
on the different mechanisms of actions of the two drug effects of angiotensin II on glomerular cell migration,
tubular cell proliferation, and development of urinaryclasses. In addition to decreased angiotensin II forma-
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African Americans with advanced renal failure. Surpris-
ingly, this study showed a lowered plasma renin activity
and enhanced GFR during losartan on top of ACE inhib-
itor treatment. Limitations of this study include under-
dosing with losartan, since 100 mg is more effective than
50 mg on both albuminuria and blood pressure in pa-
tients with DN [29]. Furthermore, the findings of Agar-
wal et al cannot be extrapolated to other ethnic groups
due to differences in RAS activity and response to RAS
blockade [30, 31]. In another nonrandomized open-
labeled study of nine patients with nondiabetic renal
disease, seven patients received both monotherapies in
different doses followed by 40 mg of lisinopril losartan
(50 to 150 mg) [32]. Dual blockade reduced proteinuria
85% from placebo, whereas 40 mg of lisinopril had sig-
nificantly less antiproteinuric effect of 75% from pla-Fig. 3. Linear regression analysis between the change in diastolic blood
cebo. Dual blockade had similar antihypertensive effectspressure and the change in plasma renin concentration (LN) in type 1
patients with diabetic nephropathy (DN) treated with dual blockade compared to lisinopril 40 mg [32].
of the renin-angiotensin system (RAS). Several papers have reported on the effect of combin-
ing submaximal doses ACE inhibition and ARB, but
carry the risk of underestimating the effect of monother-
apy with ACE inhibition. The CALM-study [6] of typeprotein excretion may be mediated through the angio-
tensin II type 2 receptor [22–24]. Standard ARBs do not 2 diabetic patients with microalbuminuria and hyperten-
sion found an enhanced reduction in blood pressure andantagonize the type 2 receptor. Therefore, treatment
with both ACE inhibitors and ARBs may offer syner- a tendency toward a more pronounced drop in urinary
albumin excretion by dual blockade (16 mg candesartangistic blockade of the RAS, not obtainable with either
drug alone. In accordance, in an animal model Komine cilexetil and 20 mg lisinopril) compared to therapy with
either agent alone. Once DN has developed, we haveet al [25] demonstrated that dual RAS blockade with
captopril (1.7 mg/day) losartan (0.7 mg/day) treatment recently demonstrated a beneficial short-term effect of
dual blockade of the RAS in the subset of diabetic pa-further reduces renal tissue angiotensin II level com-
pared to treatment with captopril (2.4 mg/d) or losartan tients with DN and albuminuria 1 g/24 hours  blood
pressure 135/85 mm Hg, despite treatment with ACE(1.7 mg/d) alone. Furthermore, tripling the dose of capto-
pril (7.5 mg/day) or losartan (6.0 mg/day) did not reduce inhibitors (20 mg enalapril/lisinopril or equivalents) and
diuretics [7, 8]. In nondiabetic renal disease, a superiorthe intrarenal angiotensin II to the level observed with
low-dose dual blockade therapy [25]. The mechanism effect of dual blockade compared to single blockade
was reported in several short-term open-label studiesunderlying the lower renal tissue angiotensin II during
ARB is not completely understood, but may involve [33–36]. The COOPERATE trial [9] is the first long-
term trial addressing the effect of dual blockade on pri-decreased binding to the receptor and internalization of
angiotensin II in the presence of a receptor blocker mary renal end points. This double-blind, randomized
study of 263 patients with nondiabetic renal disease dem-and/or increased degradation of angiotensin II. The au-
thors concluded that the superior reduction in renal tis- onstrated that 11% of patients on 100 mg losartan 
3 mg of trandolapril developed doubling of serum creati-sue angiotensin II with ACE inhibitors plus ARB pro-
vides a mechanism to understand the synergism of this nine or reached end-stage renal disease during a median
of 3 years of follow-up, whereas 23% reached the pri-combination in reducing proteinuria and blood pressure.
On the other hand, conflicting results from studies of mary end points during treatment with either monother-
apies (P  0.02) [9].dual blockade of the RAS on blood pressure and urinary
protein excretion in subtotally nephrectomized rats have In this study, we demonstrate an additional effect of
dual blockade on albuminuria and blood pressure usingbeen reported [26, 27].
Very limited information exists on the impact of dual maximal recommended doses that is comparable to what
was obtained in our previous study using lower dose ofblockade of the RAS compared to maximal recom-
mended doses of ACE inhibitors in humans. Agarwal ACE inhibitor and the same dose of irbesartan [7]. Fur-
thermore, we saw an increase in plasma renin concentra-[28] reported that adding 50 mg of losartan daily to 40 mg
of lisinopril daily had no effect on blood pressure and tion of 64% in the present study equal to the 69% seen
in our first study [7], indicating the same degree of incom-proteinuria in a small heterogeneous group of predomi-
nantly severely obese, hypertensive, proteinuric diabetic plete blockade of the RAS on 20 mg and 40 mg of enal-
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april/lisinopril (or equivalent) alone. This adds further with ACE inhibition alone in type 1 patients with DN.
Long-term trials are needed to further establish the roleevidence to the idea of synergistic effect of using both
ACE inhibitors and ARB to interrupt the RAS. of dual blockade of the RAS.
Even though using maximal recommended doses of
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